Longevity Science 2026: The Supplements and Protocols Backed by Research

The Longevity Field Has Matured — Most Supplements Still Have Not

The longevity supplement market exceeded $65 billion globally in 2025. The amount of that spending supported by rigorous human clinical evidence remains vanishingly small. This is the uncomfortable reality that the longevity space's loudest voices rarely acknowledge. What follows is an evidence-stratified assessment of every major longevity intervention as of March 2026, ranked by the quality of supporting data rather than the enthusiasm of their proponents.

Tier 1: Strong Human Evidence

Exercise — The Only Proven Longevity Intervention

Before examining any supplement, the baseline must be established. A 2022 meta-analysis in the British Journal of Sports Medicine covering 196 studies and over 30 million participants found that 150 minutes of moderate-intensity exercise per week reduced all-cause mortality by 31%. Increasing to 300 minutes weekly pushed that reduction to 37%. No supplement, drug, or intervention in human history has matched these numbers in controlled trials. The dose-response curve flattens significantly above 300 minutes weekly, suggesting diminishing returns beyond roughly 45 minutes daily.

Strength training adds independent mortality reduction. A 2023 systematic review found that resistance training two or more sessions per week reduced all-cause mortality by an additional 14% beyond cardio alone. The combination of Zone 2 cardio (covered in depth in our dedicated guide) with two to three strength sessions weekly represents the single most evidence-backed longevity protocol available.

Omega-3 Fatty Acids (EPA/DHA)

The VITAL trial (25,871 participants, 5.3 years) showed a 28% reduction in heart attacks with 1g daily omega-3 supplementation. The REDUCE-IT trial demonstrated a 25% reduction in major cardiovascular events with 4g daily icosapent ethyl (pure EPA) in statin-treated patients with elevated triglycerides. The STRENGTH trial, using a mixed EPA/DHA formulation, showed no benefit — suggesting that EPA specifically, rather than combined omega-3, may drive cardiovascular protection.

Dosing consensus in 2026 centers on 2 to 4g combined EPA/DHA daily, with a preference for EPA-dominant formulations. Quality matters: third-party tested brands that verify heavy metal content and actual EPA/DHA concentrations are essential. Blood testing for the Omega-3 Index (target: 8 to 12%) provides objective dosing guidance.

Vitamin D

The evidence for vitamin D is nuanced. The VITAL trial showed no overall mortality reduction with 2,000 IU daily supplementation. However, subgroup analysis revealed significant benefits in vitamin D-deficient populations (baseline 25-hydroxyvitamin D below 20 ng/mL), with a 23% reduction in cancer mortality. A 2024 Lancet meta-analysis covering 81 trials confirmed mortality benefits only in deficient individuals.

The practical takeaway: test your levels. If 25-hydroxyvitamin D is below 30 ng/mL, supplement with 2,000 to 5,000 IU daily and retest at 90 days. If levels are already 40 to 60 ng/mL, additional supplementation shows no measurable benefit in current data. The population-level recommendation of universal supplementation is not supported; targeted supplementation based on blood work is.

Tier 2: Promising Human Data, Incomplete Picture

Creatine Monohydrate

Beyond its well-established role in exercise performance, creatine has emerging evidence for neuroprotection and cognitive enhancement, particularly in aging populations and sleep-deprived states. A 2023 systematic review in Experimental Gerontology found that creatine supplementation (3 to 5g daily) in adults over 60 improved cognitive processing speed, working memory, and executive function. The mechanism appears related to enhanced cerebral bioenergetics — the brain consumes roughly 20% of total body energy, and creatine serves as a phosphate buffer for ATP regeneration.

At 3 to 5g daily, creatine monohydrate has one of the strongest safety profiles of any supplement, with over 30 years of human research and no confirmed adverse effects in healthy populations. The decades-old concerns about kidney damage have been thoroughly debunked in individuals with normal renal function. Loading phases (20g daily for a week) are unnecessary — consistent daily dosing achieves saturation within three to four weeks.

Magnesium

Roughly 50% of Americans consume less than the recommended daily allowance of magnesium. A 2024 meta-analysis in the European Journal of Clinical Nutrition found that magnesium supplementation was associated with a 10% reduction in all-cause mortality, driven primarily by cardiovascular and metabolic benefits. The effect was strongest in populations with documented deficiency.

Form matters significantly. Magnesium glycinate offers superior bioavailability and tolerability versus magnesium oxide (which has roughly 4% absorption). Magnesium L-threonate shows specific promise for cognitive function based on animal models and preliminary human trials, though large-scale RCTs are still pending. Dosing of 200 to 400mg elemental magnesium daily, ideally split between morning and evening, aligns with current evidence.

Tier 3: Interesting Mechanisms, Weak Human Evidence

NMN and NR (NAD+ Precursors)

The NAD+ precursor space remains one of the most overhyped areas in longevity. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) reliably raise blood NAD+ levels in humans — this is well-established. What remains unestablished is whether raising NAD+ levels translates to meaningful health or longevity outcomes in humans.

The largest NMN trial to date, published in early 2025 with 240 participants over 60 weeks, showed increased NAD+ levels but no significant improvements in primary endpoints of aerobic capacity, muscle function, or metabolic markers versus placebo. NR trials have shown similarly mixed results, with the CHROMADOSE study finding no cardiovascular benefit at doses up to 1,000mg daily.

The animal data (primarily from David Sinclair's lab at Harvard) remains compelling — lifespan extension, restored fertility in aged mice, and improved metabolic function. But the translation gap between mouse models and human outcomes has been the story of NAD+ research for a decade. At $50 to $150 per month, NMN/NR supplementation is a bet on mechanism-based reasoning rather than demonstrated human efficacy.

Resveratrol

Resveratrol's story is a cautionary tale about translating cell culture and animal data to humans. Despite extraordinary in vitro results showing SIRT1 activation and lifespan extension in yeast and mice, human trials have been consistently underwhelming. A 2024 comprehensive review in Nature Aging concluded that oral resveratrol at typical supplement doses (250 to 1,000mg daily) has poor bioavailability (less than 1% reaches systemic circulation intact) and has failed to demonstrate clinically meaningful benefits in any large human RCT for cardiovascular disease, diabetes, cognitive function, or cancer prevention.

David Sinclair, once resveratrol's most prominent advocate, has notably reduced his emphasis on the compound in recent years. The scientific consensus in 2026 is that resveratrol is not harmful at typical doses but is unlikely to provide meaningful longevity benefits. The money is better allocated elsewhere.

Spermidine

Spermidine, a naturally occurring polyamine found in wheat germ, soybeans, and aged cheese, has gained attention for its role in autophagy induction. A 2018 epidemiological study in the American Journal of Clinical Nutrition found that higher dietary spermidine intake was associated with reduced mortality, but this observational data cannot establish causation. The SmartAge trial (2024) showed modest cognitive improvements in older adults with subjective cognitive decline using 1.2mg daily spermidine supplementation over 12 months, but the effect sizes were small and the trial lacked statistical power.

Tier 4: Popular But Unsupported

Collagen Peptides

Collagen supplements dominate the beauty and wellness market, but the longevity claims are unfounded. Oral collagen is digested into amino acids like any other protein. While some trials show modest improvements in skin hydration and joint comfort, there is zero evidence for lifespan extension or meaningful disease prevention. At a fundamental biochemistry level, the body does not absorb intact collagen molecules and redirect them to specific tissues — the marketing narrative contradicts basic digestive physiology.

Turkesterone and Ecdysteroids

Despite social media hype, the 2025 systematic review in the Journal of the International Society of Sports Nutrition found no significant effect of ecdysteroid supplementation on muscle mass, strength, or body composition in any controlled human trial. The single frequently cited positive study (Isenmann et al., 2019) had severe methodological limitations including no verification of supplement content.

The Protocol That Actually Has Evidence

Based on the totality of human evidence through March 2026, the evidence-ranked longevity protocol looks like this. First, 150 to 300 minutes weekly of Zone 2 cardio plus two to three resistance training sessions — this is non-negotiable and more impactful than everything else combined. Second, 2 to 4g EPA/DHA omega-3 daily from a third-party tested source. Third, vitamin D at 2,000 to 5,000 IU daily if blood levels are below 30 ng/mL. Fourth, creatine monohydrate at 3 to 5g daily. Fifth, magnesium glycinate at 200 to 400mg daily. Sixth, optimize sleep to seven to nine hours nightly with consistent timing.

Everything beyond this list represents either a reasonable bet on incomplete data (NAD+ precursors, spermidine) or marketing outpacing science (collagen, turkesterone, most "longevity blends"). The discipline to ignore noise and execute on proven fundamentals is, ironically, the hardest longevity intervention of all.